Lupin is set to enhance its contract manufacturing operations for international clients with the appointment of Abdelaziz Toumi as the new CEO of its subsidiary, Lupin Manufacturing Solutions (LMS). LMS is gearing up to expand its Contract Development and Manufacturing Operations (CDMO) business globally, as announced by the pharmaceutical giant on June 17.
Abdelaziz Toumi, a seasoned leader with over 20 years of experience in the biotech, pharma, and CDMO sectors across Europe, North America, and Asia, will helm LMS. His previous leadership roles include positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma. Based in Switzerland, Toumi will also dedicate substantial time to overseeing operations in India.
Lupin’s Managing Director, Nilesh Gupta, stated, “Abdel brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”
Lupin is the third-largest pharmaceutical company in the US by prescription volume, operating 15 manufacturing sites and 7 research centers worldwide. In September 2023, Lupin signed a business transfer agreement with LMS to transfer two API manufacturing sites and select R&D operations to the subsidiary.
